These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 18175284)
1. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Franchini M; Montagnana M; Targher G; Lippi G Semin Thromb Hemost; 2007 Nov; 33(8):787-97. PubMed ID: 18175284 [TBL] [Abstract][Full Text] [Related]
3. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977 [TBL] [Abstract][Full Text] [Related]
4. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Chapman K; Seldon M; Richards R Semin Thromb Hemost; 2012 Feb; 38(1):47-54. PubMed ID: 22314603 [TBL] [Abstract][Full Text] [Related]
5. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity]. Kato S; Fujimura Y Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861 [TBL] [Abstract][Full Text] [Related]
6. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Furlan M; Lämmle B Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108 [TBL] [Abstract][Full Text] [Related]
7. Methodologies and clinical utility of ADAMTS-13 activity testing. Just S Semin Thromb Hemost; 2010 Feb; 36(1):82-90. PubMed ID: 20391299 [TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245 [TBL] [Abstract][Full Text] [Related]
9. The potential therapeutic benefit of targeting ADAMTS13 activity. Eerenberg ES; Levi M Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in thrombotic thrombocytopenic purpura. Sadler JE; Moake JL; Miyata T; George JN Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695 [TBL] [Abstract][Full Text] [Related]
11. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Peyvandi F; Siboni SM; Lambertenghi Deliliers D; Lavoretano S; De Fazio N; Moroni B; Lambertenghi Deliliers G; Mannuccio Mannucci P Br J Haematol; 2006 Jul; 134(2):187-95. PubMed ID: 16846477 [TBL] [Abstract][Full Text] [Related]
12. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Furlan M Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284 [TBL] [Abstract][Full Text] [Related]
13. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. Tsai HM; Lian EC N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246 [TBL] [Abstract][Full Text] [Related]
18. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene]. Schiphorst RH; van de Kar NC; van den Heuvel LP Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551 [TBL] [Abstract][Full Text] [Related]